Automated Ex Vivo Isolation, Transduction, And Expansion Of CD137-Positive Tumor-Reactive T Cells On The CliniMACS Prodigy®

Manufacturing tumor-reactive T-cell therapies for solid tumors requires careful coordination across stimulation, selection, expansion, and, in some cases, genetic modification. A closed, automated workflow can help reduce manual handling while supporting a more standardized path from tumor tissue or blood-derived starting material to clinically relevant cell numbers. By combining antigen-specific stimulation with CD137-based enrichment, the process enables the isolation and expansion of highly pure tumor-reactive and virus-specific T-cell populations while preserving functional activity after culture. The same workflow also supports CAR transduction and the expansion of outgrown TILs, demonstrating flexibility across multiple cell therapy strategies.

For teams working to advance next-generation T-cell therapies, explore a practical route for improving consistency, scalability, and manufacturing efficiency.